Biotinylated Human HLA-A*11:01&B2M&LMP2 (SSCSSCPLTK) Monomer Protein
Beta LifeScience
SKU/CAT #: BLK-01673P-100UG

Biotinylated Human HLA-A*11:01&B2M&LMP2 (SSCSSCPLTK) Monomer on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.
Biotinylated Human HLA-A*11:01&B2M&LMP2 (SSCSSCPLTK) Monomer Protein
Beta LifeScience
SKU/CAT #: BLK-01673P-100UG
Collections: Fc receptors, High-quality recombinant proteins
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.
Product Overview
Description | Recombinant Biotinylated Human LMP2(HLA-A*11:01) Protein is expressed from HEK293 with with His tag and Avi tag at the C-Terminus.It contains Gly25-Thr305(HLA-A*11:01),Ile21-Met119(B2M) and SSCSSCPLTK peptide. |
Purity | > 95% as determined by Tris-Bis PAGE;> 95% as determined by HPLC |
Accession | AAV53343.1(HLA-A*11:01)&P61769(B2M)&SSCSSCPLTK |
Target Symbol | HLA-A*11:01&B2M&LMP2 (SSCSSCPLTK) Monomer |
Synonyms | MHC; RMF; LMP2; LMP-2; Macropain chain 7; Proteasome chain 7; PSMB9; RING12 |
Species | Human |
Expression System | HEK293 |
Tag | C-His-Avi |
Expression Range | Gly25-Thr305(HLA-A*11:01),Ile21-Met119(B2M)and SSCSSCPLTK peptide |
Mol. Weight | The protein has a predicted MW of 50.4 kDa. Due to glycosylation, the protein migrates to 51-60 kDa based on Tris-Bis PAGE result. |
Form | Lyophilized |
Formulation | Lyophilized from 0.22um filtered solution in 20mM PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization. |
Endotoxin | Less than 1EU per ug by the LAL method. |
Storage | Reconstituted protein stable at -80°C for 12 months, 4°C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. |
Shipping | Shipped at ambient temperature. |
Gene Background | The immunoproteasome, having been linked to neurodegenerative diseases and hematological cancers, has been shown to play an important role in MHC class I antigen presentation. The development of molecular probes that selectively inhibit the major catalytic subunit, LMP2, of the immunoproteasome,LMP2-rich cancer cells compared to LMP2-deficient cancer cells are more sensitive to growth inhibition by the LMP2-specific inhibitor, implicating an important role of LMP2 in regulating cell growth of malignant tumors that highly express LMP2. |